Natera (NTRA) Expected to Announce Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is projected to release its earnings data after the market closes on Thursday, February 27th. Analysts expect Natera to post earnings of ($0.42) per share and revenue of $447.91 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Natera Stock Performance

Shares of NTRA opened at $156.00 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market capitalization of $20.60 billion, a price-to-earnings ratio of -88.64 and a beta of 1.66. The company’s 50 day simple moving average is $167.49 and its 200 day simple moving average is $146.50. Natera has a 1 year low of $70.71 and a 1 year high of $183.00.

Analysts Set New Price Targets

Several brokerages recently commented on NTRA. Guggenheim upped their price target on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Robert W. Baird upped their price target on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Craig Hallum upped their price target on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group upped their price target on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $170.94.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Solomon Moshkevich sold 4,858 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22. Following the transaction, the insider now owns 114,912 shares in the company, valued at $19,143,190.08. This trade represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 295,772 shares of company stock valued at $49,741,699. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.